Neogenomics Inc reports results for the quarter ended December 31 - Earnings Summary

NeoGenomics

18/02/2025 14:31

* Neogenomics Inc  NEO.OQ  reported quarterly adjusted
earnings of
4 cents​​ per share for the quarter ended December 31, higher
than the same quarter last year, when the company reported EPS
of 3 cents.  The mean expectation of fifteen analysts for the
quarter was for earnings of 3 cents per share. Wall Street
expected results to range from 1 cents to 7 cents per share.
    * Revenue rose 10.6% to $172.00 million from a year ago;
analysts
expected $173.18 million. 
    * Neogenomics Inc's reported EPS for the quarter was a loss
of 12
cents​.
    * The company reported a quarterly loss of $15.32 million.
    * Neogenomics Inc shares had fallen by 12.5% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 8.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the healthcare
facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Neogenomics Inc
is $19.00 
This summary was machine generated from LSEG data February 18 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      0.03           0.04           Beat
 Sep. 30 2024      0.01           0.05           Beat
 Jun. 30 2024      0.00           0.03           Beat
 Mar. 31 2024      -0.05          -0.02          Beat